Please use this identifier to cite or link to this item:
https://dora.health.qld.gov.au/qldresearchjspui/handle/1/579
Title: | A randomised controlled trial of Heparin versus EthAnol Lock THerapY for the prevention of Catheter Associated infecTion in Haemodialysis patients - The HEALTHY-CATH trial | Authors: | Broom, J. K. Krishnasamy, R. Playford, E. G. Johnson, D. W. Hawley, C. M. |
Issue Date: | 2012 | Source: | 13, (1), 2012 | Journal: | BMC Nephrology | Abstract: | Background: Tunnelled central venous dialysis catheter use is significantly limited by the occurrence of catheter-related infections. This randomised controlled trial assessed the efficacy of a 48 hour 70% ethanol lock vs heparin locks in prolonging the time to the first episode of catheter related blood stream infection (CRBSI). Methods. Patients undergoing haemodialysis (HD) via a tunnelled catheter were randomised 1:1 to once per week ethanol locks (with two heparin locks between other dialysis sessions) vs thrice per week heparin locks. Results: Observed catheter days in the heparin (n=24) and ethanol (n=25) groups were 1814 and 3614 respectively. CRBSI occurred at a rate of 0.85 vs. 0.28 per 1000 catheter days in the heparin vs ethanol group by intention to treat analysis (incident rate ratio (IRR) for ethanol vs. heparin 0.17; 95%CI 0.02-1.63; p=0.12). Flow issues requiring catheter removal occurred at a rate of 1.6 vs 1.4 per 1000 catheter days in the heparin and ethanol groups respectively (IRR 0.85; 95% CI 0.20-3.5 p =0.82 (for ethanol vs heparin). Conclusions: Catheter survival and catheter-related blood stream infection were not significantly different but there was a trend towards a reduced rate of infection in the ethanol group. This study establishes proof of concept and will inform an adequately powered multicentre trial to definitively examine the efficacy and safety of ethanol locks as an alternative to current therapies used in the prevention of catheter-associated blood stream infections in patients dialysing with tunnelled catheters. Trial Registration. Australian New Zealand Clinical Trials Registry ACTRN12609000493246. 2012 B room et al.; licensee BioMed Central Ltd. | DOI: | http://dx.doi.org/10.1186/1471-2369-13-146 499 |
Resources: | http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed11&AN=2013007578 | Keywords: | Catheter related blood stream infection (CRBSI)Central venous catheter;Ethanol;Haemodialysis (HD);Lock therapy;Prophylaxis;adult;antibiotic therapy;article;blood culture;catheter infection/pc [Prevention];clinical article;controlled study;drug efficacy;Enterobacter cloacae;female;hemodialysis patient;human;male;randomized controlled trial;Staphylococcus aureus;Staphylococcus hominis;treatment duration;alcohol/ct [Clinical Trial];alcohol/cm [Drug Comparison];alcohol/iv [Intravenous Drug Administration];dicloxacillin;gentamicin;heparin/ct [Clinical Trial];heparin/cm [Drug Comparison];vancomycin | Type: | Article |
Appears in Sites: | Sunshine Coast HHS Publications |
Show full item record
Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.